BridgeBio's Phase 3 trial of Oral Infigratinib in Achondroplasia shows significant body proportionality improvement, hitting primary endpoint (p<0.0001) - AHV at Week 52.The PROPEL 3 study achieved success by meeting the primary goal of demonstrating a significant change in AHV compared to baseline at Week 52, with a p-value of less than 0.0001.
